Miracle Leaf® Health Centers
Semaglutide is a GLP-1 receptor agonist, a type of medication that mimics a hormone your gut releases after eating. It slows digestion and acts on the brain’s appetite signalling, which is why it comes up so often in weight loss and GLP-1 telehealth.
What semaglutide actually is
Semaglutide itself is the active ingredient. It is sold under different brand names depending on the condition the product is approved to treat:
- Ozempic® is FDA-approved for type 2 diabetes.
- Wegovy® is FDA-approved specifically for chronic weight management in adults with obesity, or with overweight plus a weight-related condition.
Both contain the same active ingredient, at different approved uses and often different dosing. The FDA-approved Wegovy® label states the approval covers adults with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with a condition like high blood pressure, high cholesterol, or type 2 diabetes. That label, not general marketing language, is the source for who the approval is written for.
Approval attaches to a specific product rather than to the molecule in general. A product containing semaglutide is not automatically covered by Wegovy®‘s approval, and that difference matters when you are deciding what you are being offered. Ask the provider which product they are prescribing and what its approval status is.
What a provider evaluates
Miracle Leaf® does not perform this evaluation. A licensed provider conducts the visit and decides what is appropriate. A typical evaluation covers your health history, current medications, weight-related conditions, and whether semaglutide, or a related option like tirzepatide, is a reasonable fit for you specifically. If appropriate, the provider issues the prescription, not Miracle Leaf®.
What to expect day to day
Most telehealth programs start at a low dose and increase it gradually over several weeks, a process called titration, which is meant to reduce side effects while your body adjusts.
The most commonly reported side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal discomfort. These tend to be most noticeable right after starting or right after a dose increase, and often ease over time. Your provider will walk you through what to watch for and when to reach out, since dose adjustments and follow-up care are part of an ongoing telehealth relationship rather than a one-time visit.
For what a specific medication costs and whether it is available to you, ask the licensed provider who conducts your evaluation. Pricing depends on the product prescribed and on the pharmacy that fills it, so a figure quoted here would not reliably describe what you are offered.
How this fits with other options
If you are comparing options, our tirzepatide page covers a dual-mechanism medication, and our oral semaglutide page covers the pill form and where its FDA approval status differs from the injectable. Our metformin page covers an older, non-injectable option some providers use alongside or instead of a GLP-1. Which of these is appropriate is a decision for the provider who evaluates you, based on your health history rather than on what you arrived intending to ask for.
Sources
- FDA-approved label, Wegovy® (semaglutide) injection, NDA 215256, June 2021 (accessdata.fda.gov), for the approved indication and the BMI criteria referenced above
- FDA approval record for Ozempic® (semaglutide) injection, for the type 2 diabetes indication